A drug delivery carrier material capable of promoting drug entry into cells, and preparation method and application thereof
Through the use of docosahexaenoic acid-polyethylene glycol conjugates, the problem of slow uptake of PEG-modified nanoparticles in target cells was solved, and the drug was quickly reached to tumor cells, improving the therapeutic effect, and ensuring Biocompatibility and safety of the material.
Patent Information
- Application Number
- CN202211104370.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2022-09-09
- Publication Date
- 2024-12-03
- Estimated Expiration
- 2042-09-09
AI Technical Summary
Although the existing polyethylene glycol (PEG) modified nanoparticles improve the water solubility and circulation time of the drug, they reduce the uptake rate of target cells by drugs, hinder the rapid reach of drugs to tumor cells, resulting in poor treatment results.
Using docosahexaenoic acid-polyethylene glycol conjugate (DHA-PEG), the polyunsaturated fatty acid docosahexaenoic acid and polyethylene glycol are directly or indirectly covalently coupled through chemical cross-linking method. The combination forms a conjugate with hydrophilic and hydrophobic sections, which is used to prepare nanomicrobes, modify prodrug self-assemblies and liposomes, and improve the solubility of the drug and endocytosis rate of cells.
It significantly improves the uptake rate and therapeutic effect of drugs in tumor cells, extends the circulation time of drugs in the body, reduces systemic adverse reactions, and has high biocompatibility and safety of materials, which is suitable for clinical applications.
Smart Images

Figure CN116178699B_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the technical field of nano drug carrier materials, and in particular to a drug delivery carrier material capable of promoting drug entry into cells, and a preparation method and application thereof. Background Art
[0002] In the past decade, the incidence and mortality of malignant tumors have been on the rise, and it has become the second leading cause of death in the world. The current treatment methods for tumors include surgery, radiotherapy, chemotherapy and targeted therapy. Targeted drugs are corresponding therapeutic drugs designed for tumor targets. When the drugs enter the body, they will specifically select carcinogenic sites and bind to each other to cause tumor cells to die specifically without affecting the normal tissue cells around the tumor. They are accurate and gentle, with few side effects.
[0003] However, most of the drugs currently used in the clinic to treat malignant tumors have problems such as off-target effects, drug resistance, and varying degrees of adverse toxicity. In addition, first-line anticancer drugs, including taxanes, camptothecins, and various molecular targeted drugs, often have extremely low water solubility, which requires the above drugs to be administered orally or with other excipients to assist in in vivo delivery, increasing the patient's physical burden. Therefore, we urgently need new strategies to improve the in vivo performance of drugs.
[0004] Drug delivery systems provide a method to improve the pharmacokinetics of therapeutic drugs and regulate their biodistribution, delivering drugs to target cells or tumor microenvironment to improve their efficacy while reducing systemic adverse reactions. Various biomaterial-based delivery systems, such as conjugated drugs, liposomes, nanoparticles, and cell-derived systems, have been developed.
[0005] The development of polyethylene glycol (PEG) materials and their functional modification are one of the development focuses of nano-delivery systems in recent years. The surface of nanoparticles is modified by PEGylated materials to improve the water solubility of drugs. The PEG layer formed can prevent serum protein adsorption and uptake by the mononuclear phagocyte system, and prolong the circulation time in the body. PEGylated phospholipids are currently widely used nanomaterials, such as 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-polyethylene glycol (DSPE-MPEG2000), which has both the amphiphilic properties of phospholipids and the hydrophilic polymer properties of PEG. In recent years, its application in drug carriers such as long-circulating liposomes, polymer micelles, and long-circulating nanoparticles has achieved rapid development.
[0006] However, although the nanoparticles modified by polyethylene glycol (PEG) help to avoid the clearance of macrophages, they also reduce the uptake of drugs by target cells such as tumor cells, which is not conducive to the rapid arrival of anticancer drugs at the site of action, and cannot achieve the effect of rapid killing of tumor cells. Furthermore, the presence of phospholipids in PEGylated phospholipids easily causes nanoparticles to carry a stronger negative charge, which further hinders the entry of nanoparticles into cells by reducing the interaction between cell membranes and nanoparticles. Therefore, how to improve drug carrier materials, while retaining the advantages of PEG, accelerate the uptake of nanoparticles by tumor cells, and ultimately effectively improve the therapeutic effect of anticancer drugs, is a problem that those skilled in the art need to solve. Summary of the invention
[0007] The purpose of the present invention is to provide a novel drug carrier material for drug delivery, which can not only improve the water solubility of hydrophobic drugs and prolong the drug circulation time in the body, but also improve the drug uptake by target cells such as tumor cells, thereby effectively improving the drug treatment effect.
[0008] To achieve the above object, the present invention adopts the following technical solution:
[0009] The invention provides a docosahexaenoic acid-polyethylene glycol conjugate, which comprises a hydrophilic segment and a hydrophobic segment, wherein the hydrophilic segment is a methoxy polyethylene glycol molecule with a molecular weight of 500 to 10,000, and the hydrophobic segment is 1 to 4 docosahexaenoic acid molecules.
[0010] The present invention directly connects a non-toxic polyethylene glycol chain (PEG) having good biocompatibility and biodegradability with a polyunsaturated fatty acid, namely docosahexaenoic acid (DHA), or couples them through a linker to obtain a DHA-PEG conjugate. The conjugate is coupled by a chemical cross-linking method, such as condensation reactions such as esterification and amidation.
[0011] Preferably, the structural formula of the DHA-PEG conjugate is as shown in any one of formulas (I) to (X),
[0012]
[0013]
[0014] Among them, the structural formula of R1 is:
[0015] The structural formula of R2 is: n is an integer from 10 to 230.
[0016] Preferably, n is an integer of 23 to 227, more preferably, n is 23, 45, 114, or 227.
[0017] The present invention also provides a method for preparing the above-mentioned docosahexaenoic acid-polyethylene glycol (DHA-PEG) conjugate, comprising: in the presence of a condensing agent and a catalyst, docosahexaenoic acid and methoxy polyethylene glycol having a structural formula as shown in formula (XI) and R being a hydroxyl group or an amino group are subjected to a condensation reaction to prepare the DHA-PEG conjugate;
[0018] Alternatively, under the action of a condensing agent and a catalyst, docosahexaenoic acid is first subjected to a condensation reaction with a linker compound having two or more linking groups, wherein the linking groups are selected from hydroxyl, amino, and carboxyl groups; and then subjected to a condensation reaction with a methoxy polyethylene glycol having a structural formula as shown in formula (XI), wherein R is a hydroxyl, amino, or carboxyl group, to obtain a DHA-PEG conjugate.
[0019]
[0020] Wherein n is an integer from 10 to 230.
[0021] Preferably, the linker compound is one of ethylene glycol, propylene glycol, butylene glycol, ethylenediamine, propylenediamine, butylenediamine, lysine, and isopropylglycerol.
[0022] Furthermore, the structural formulas of the above linker compounds are:
[0023]
[0024] Further preferably, in the presence of a condensing agent and a catalyst, docosahexaenoic acid is first subjected to an esterification reaction with an equivalent amount of ethylene glycol, propylene glycol or butylene glycol, and then subjected to an esterification reaction with an equivalent amount of methoxypolyethylene glycol-carboxyl (mPEG-COOH) having a structural formula as shown in formula (XI) to obtain a DHA-PEG conjugate having structural formulas as shown in (III)-(V).
[0025] Alternatively, in the presence of a condensing agent and a catalyst, docosahexaenoic acid is first subjected to an amidation reaction with an equivalent amount of ethylenediamine, propylenediamine or butylenediamine, and then subjected to an amidation reaction with an equivalent amount of methoxypolyethylene glycol-carboxyl (mPEG-COOH) of a structural formula such as that shown in formula (XI) to obtain a DHA-PEG conjugate of a structural formula such as that shown in (VI)-(VIII).
[0026] Alternatively, in the presence of a condensing agent and a catalyst, docosahexaenoic acid is first reacted with N-hydroxysuccinimide to synthesize succinimidyl-modified docosahexaenoic acid, which is then subjected to a condensation reaction with D-lysine at an equivalent ratio of 2:1, and then subjected to an amidation reaction with methoxypolyethylene glycol-amino (mPEG-NH2) as shown in formula (XI) to obtain a DHA-PEG conjugate as shown in formula (IX).
[0027] Alternatively, in the presence of a condensing agent and a catalyst, methoxypolyethylene glycol-carboxyl (mPEG-COOH) having a structural formula as shown in formula (XI) and isopropyl glycerol are first subjected to an esterification reaction to synthesize polyethylene glycol-isopropyl glycerol, and then the protecting group is removed under the catalysis of an organic acid to expose two hydroxyl sites, which are further reacted with two equivalents of docosahexaenoic acid to obtain a DHA-PEG conjugate having a structural formula as shown in formula (X).
[0028] Preferably, the condensing agent is 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide (EDC), and the catalyst is 4-dimethylaminopyridine (DMAP) or N,N-diisopropylethylamine (DIEA).
[0029] Preferably, the reaction solvent is dichloromethane or chloroform.
[0030] Preferably, the reaction temperature is 40 to 50° C. and the reaction time is 2 to 72 hours.
[0031] The present invention shows that the docosahexaenoic acid-polyethylene glycol conjugate can be used as a drug carrier material for a variety of purposes, including but not limited to: preparing drug-loaded nanomicelles by encapsulating hydrophobic anticancer drugs; modifying prodrug self-assemblies to stabilize and optimize particle performance; and as a component of liposomes to prepare liposomes through liposome technology.
[0032] The present invention uses a cell endocytosis experiment to show that the nanoparticles prepared by the docosahexaenoic acid-polyethylene glycol conjugate have a much faster endocytosis rate than the commercially available material DSPE-PEG 2k The prepared nanoparticles confirmed that the DHA-PEG conjugate has the effect of promoting drug entry into cells. The results of cytotoxicity experiments further showed that the prodrug self-assembly modified by the DHA-PEG conjugate has higher anti-tumor activity. The results of animal toxicity experiments showed that the DHA-PEG conjugate has biosafety as a drug carrier.
[0033] Therefore, the present invention provides the use of docosahexaenoic acid-polyethylene glycol conjugate as a drug delivery carrier material in the preparation of a pharmaceutical preparation.
[0034] Specifically, the present invention provides an application of the docosahexaenoic acid-polyethylene glycol conjugate to prepare drug-loaded nanomicelles, and the drug-loaded nanomicelles are prepared by encapsulating hydrophobic drugs (such as anti-tumor drugs such as cabazitaxel), which can significantly improve the solubility of hydrophobic drugs, realize intravenous injection of drugs, and improve the bioavailability of drugs.
[0035] The application includes: dissolving the docosahexaenoic acid-polyethylene glycol conjugate and the hydrophobic drug in organic solvents respectively, mixing the two and injecting them into the aqueous phase to form drug-loaded nano micelles. Optionally, separating the nanoparticles from the mixed solution.
[0036] Preferably, in the above method, the concentration of docosahexaenoic acid-polyethylene glycol conjugate in the organic solvent is 0.01-80.00 mg / mL, the concentration of the hydrophobic drug is 0.01-2.00 mg / mL, and the mass ratio is 1-40:1, and the nanoparticles are prepared by self-assembly.
[0037] The above method can prepare nanoparticles with an average particle size of 5-200 nm.
[0038] The present invention also provides an application of the docosahexaenoic acid-polyethylene glycol conjugate modified prodrug self-assembly, which comprises: dissolving the docosahexaenoic acid-polyethylene glycol conjugate and the prodrug modified with fatty acid in organic solvents respectively, mixing the two and injecting them into an aqueous phase to form a docosahexaenoic acid-polyethylene glycol conjugate modified prodrug self-assembly.
[0039] The fatty acid-modified prodrug has the ability to self-assemble. During the process of self-assembly to form nanoparticles, the docosahexaenoic acid-polyethylene glycol conjugate participates in the modification on the nanoparticles, playing a role in stabilizing and optimizing the performance of the particles.
[0040] Preferably, the fatty acid is an unsaturated fatty acid, such as docosahexaenoic acid (DHA).
[0041] Preferably, in the above method, the concentration of docosahexaenoic acid-polyethylene glycol conjugate in the organic solvent is 0.01-60.00 mg / ml, the concentration of the prodrug is 0.01-3.00 mg / ml, and the nanoparticles are prepared at a mass ratio of 1-20:1.
[0042] The above method can prepare nanoparticles with an average particle size of 30-300 nm.
[0043] The present invention also provides a method for preparing liposomes by using the docosahexaenoic acid-polyethylene glycol conjugate as a liposome component through liposome technology. The liposomes are formed by the docosahexaenoic acid-polyethylene glycol conjugate, lecithin and cholesterol.
[0044] The application comprises: adding lecithin, cholesterol and docosahexaenoic acid-polyethylene glycol conjugate into a solution containing drug molecules, and self-assembling to form liposomes encapsulating the drugs.
[0045] The raw materials dissolved in the organic solvent are mixed and injected into the aqueous phase, and then the organic solvent is evaporated or the thin film dispersion method is used to obtain uniformly dispersed drug-loaded liposomes.
[0046] Preferably, the mass ratio of lecithin, cholesterol, DHA-PEG and drug is 10-40:1-8:3:1-10.
[0047] Nanoparticles with an average particle size of 20-1000 nm can be prepared by the above method.
[0048] In the above nanoparticle preparation process, the organic solvent is selected from one or more of acetone, methanol, ethanol, dichloromethane and dimethyl sulfoxide.
[0049] Furthermore, the drug preparation is a drug preparation encapsulating an anti-tumor drug, and the anti-tumor drug and carrier materials such as docosahexaenoic acid-polyethylene glycol conjugate form a nano drug delivery system targeting tumor cells.
[0050] The docosahexaenoic acid-polyethylene glycol conjugate prepared by the present invention can balance the effect of PEG on tumor cell membranes, promote the cell entry speed of nanoparticles, thereby increasing the accumulation of drugs at the tumor site and better exerting the anti-tumor effect.
[0051] The present invention has the following beneficial effects:
[0052] (1) The present invention directly or indirectly covalently couples polyethylene glycol with docosahexaenoic acid, and the obtained docosahexaenoic acid-polyethylene glycol conjugate can be used as a nanocarrier for a variety of purposes, including but not limited to preparing nanomicelles to improve the solubility of hydrophobic drugs, modifying nano self-assemblies to improve stability, preparing liposomes, etc. It opens up a new way for the in vivo delivery of nanomedicines and the construction of highly dispersed, stable, and safe green nanomedicines.
[0053] (2) Docosahexaenoic acid has unique advantages in tumor drug delivery: as a nutrient, it can promote the uptake of nanoparticles by high-energy-consuming tumor cells. Therefore, this link is used to balance the interaction between PEG and tumor cell membranes, which can effectively promote the entry rate of nanoparticles into cells and improve the anti-tumor effect of drugs.
[0054] (3) Polyethylene glycol is cheap and readily available, can be produced on a large scale, has an easily controllable molecular weight, and has good physical and chemical properties. The preparation process of the present invention is relatively simple, easy to scale up production, and has a high product yield.
[0055] (4) The docosahexaenoic acid-polyethylene glycol conjugate is metabolized in the human body to release only docosahexaenoic acid and polyethylene glycol metabolites. Docosahexaenoic acid, as a polyunsaturated fatty acid, is an essential nutrient for the human body and is harmless and beneficial to the human body. Polyethylene glycol is a non-toxic polymer with good biocompatibility and biodegradability. Therefore, the in vivo safety of the docosahexaenoic acid-polyethylene glycol conjugate is guaranteed, reducing the safety burden brought by the carrier material, which is conducive to clinical transformation. BRIEF DESCRIPTION OF THE DRAWINGS
[0056] Figure 1 This is the synthetic route of docosahexaenoic acid-polyethylene glycol conjugate 1 in Example 1.
[0057] Figure 2 This is the NMR spectrum of docosahexaenoic acid-polyethylene glycol conjugate 1 in Example 1.
[0058] Figure 3 This is the synthetic route of docosahexaenoic acid-polyethylene glycol conjugates I-VI in Example 2.
[0059] Figure 4 This is the synthetic route of docosahexaenoic acid-polyethylene glycol conjugate 2 in Example 3.
[0060] Figure 5 is the NMR spectrum of the lysine-docosahexaenoic acid conjugate in Example 3;
[0061] Figure 6 This is the NMR spectrum of docosahexaenoic acid-polyethylene glycol conjugate 2 in Example 3.
[0062] Figure 7 This is the synthetic route of docosahexaenoic acid-polyethylene glycol conjugate 3 in Example 4.
[0063] Figure 8 This is the particle size distribution of the drug-loaded nanomicelles in Example 5.
[0064] Fig. 9 This is a transmission electron microscopy image of the drug-loaded nanomicelles in Example 5.
[0065] Fig.10 This is the synthetic route of DHA-FL118 in Example 6.
[0066] Fig.11 This is the NMR spectrum of DHA-FL118 in Example 6.
[0067] Fig.12 : This is the particle size distribution of the DHA2-PEG modified prodrug self-assembly in Example 6.
[0068] Fig.13 This is a transmission electron microscopy image of the DHA2-PEG modified prodrug self-assembly in Example 6.
[0069] Fig.14 This is the particle size distribution of the drug-loaded liposomes in Example 7.
[0070] Fig.15 This is a transmission electron micrograph of the drug-loaded liposomes in Example 7.
[0071] Fig.16 This is the in vitro stability test of DF and DF / DHA2-PEG in Example 8.
[0072] Fig.17 This is the endocytosis experiment of the fluorescently labeled nanomicelles in tumor cells in Example 9.
[0073] Fig.18 This is the endocytosis experiment of the fluorescently labeled prodrug self-assembly in tumor cells in Example 10.
[0074] Fig.19 This is an in vitro cytotoxicity experiment of the DHA2-PEG modified prodrug self-assembly in Example 11.
[0075] Fig. 20 This is an in vitro toxicity experiment of docosahexaenoic acid-polyethylene glycol conjugate 2 in Example 12.
[0076] Fig.21 This is Example 13, the effect of docosahexaenoic acid-polyethylene glycol conjugate 2 on mouse body weight.
[0077] Fig. 22 This is the effect of docosahexaenoic acid-polyethylene glycol conjugate 2 on blood cells in Example 13. DETAILED DESCRIPTION
[0078] The present invention will be further described below in conjunction with specific embodiments. The following embodiments are only used to illustrate the present invention and are not intended to limit the scope of application of the present invention. Without departing from the spirit and essence of the present invention, modifications or replacements made to the inventive method, steps or conditions all belong to the scope of the present invention.
[0079] Unless otherwise specified, the experimental methods used in the following examples are all conventional methods; the materials and reagents used are reagents and materials that can be obtained from commercial channels unless otherwise specified.
[0080] mPEG 2k -NH2 was purchased from Shanghai Yayi Biotechnology Co., Ltd.;
[0081] Docosahexaenoic acid was purchased from Sigma-Aldrich, USA, CAS: 6217-54-5;
[0082] N-Hydroxysuccinimide was purchased from TCI (Shanghai) Chemical Industry Development Co., Ltd., CAS: 6066-82-6;
[0083] D-lysine was purchased from TCI (Shanghai) Chemical Industry Development Co., Ltd., CAS: 923-27-3;
[0084] Cabazitaxel was purchased from Shanghai Taosu Biochemical Technology Co., Ltd., CAS: 183133-96-2;
[0085] FL118 was purchased from Shanghai Xiyao Pharmaceutical Technology Co., Ltd., CAS: 135415-73-5.
[0086] Example 1 Synthesis of Docosahexaenoic Acid-Polyethylene Glycol Conjugate 1 (DHA-PEG)
[0087] Synthesis route such as Figure 1 As shown:
[0088] In a 100 ml round bottom flask equipped with a spherical condenser, polyethylene glycol (mPEG 2k -NH2, 2.00g, 0.95mmol), docosahexaenoic acid (DHA, 0.33g, 1.00mmol) were dissolved in 4ml of anhydrous dichloromethane, and then 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide (EDC, 0.15g, 1.00mmol) and N,N-diisopropylethylamine (DIEA, 0.13g, 1.00mmol) were quickly added dropwise. Stirred overnight at 43°C, and the reaction was observed by thin layer chromatography (developing solvent: DCM: MeOH = 20:1). When the reaction was basically completed, the reaction solution was cooled, the filtrate was evaporated to remove the solvent, and precipitated with ice ether three times to obtain a brownish yellow precipitate. The collected precipitate was separated and purified by column chromatography (DCM: MeOH = 50:1) to obtain docosahexaenoic acid-polyethylene glycol conjugate 1 (slightly yellow solid, 1.60g, yield 72.9%).
[0089] Product 1 1 H NMR spectra and peak assignments are as follows Figure 2 As shown, it was proved that polyethylene glycol and docosahexaenoic acid were successfully covalently linked, and the obtained product was confirmed to be a high-purity target product.
[0090] Example 2 Synthesis of Docosahexaenoic Acid-Polyethylene Glycol Conjugates I-VI (DHA-PEG) The synthesis process of conjugates I-VI is shown in 3.
[0091] 1. In a 100ml round-bottom flask equipped with a spherical condenser, add ethylene glycol (or one of propylene glycol, butanediol, ethylenediamine, propylenediamine, and butanediamine; 52mg, 0.846mmol), docosahexaenoic acid (DHA, 300mg, 0.705mmol) and 4-dimethylaminopyridine (DMAP, 103mg, 0.846mmol) in sequence and dissolve in 4ml of anhydrous dichloromethane, and then quickly add 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide (EDC, 131mg, 0.846mmol). Stir overnight at 43℃ and observe the reaction using thin layer chromatography (developing solvent: DCM: MeOH = 20:1). When the reaction is basically over, cool the reaction solution and then wash it with 5% citric acid, saturated sodium bicarbonate, and saturated brine respectively. Dry the organic layer with anhydrous sodium sulfate and filter it after drying completely. The filtrate is evaporated to remove the solvent. The ethylene glycol-docosahexaenoic acid conjugate (or propylene glycol, butanediol, ethylenediamine, propylenediamine, butanediamine coupling intermediate) was separated and purified by column chromatography (DCM:MeOH=20:1).
[0092] 2. Add polyethylene glycol (mPEG) 2k -COOH, 0.558g, 0.279mmol), ethylene glycol-docosahexaenoic acid conjugate (0.125g, 0.335mmol) or other intermediates and 4-dimethylaminopyridine (DMAP, 0.041g, 0.335mmol) were dissolved in 4ml of anhydrous dichloromethane, and then 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide (EDC, 0.052g, 0.335mmol) was quickly added dropwise. Stir overnight at 43°C, and the reaction was observed by thin layer chromatography (developing solvent: DCM: MeOH = 10: 1). When the reaction was basically completed, the reaction solution was cooled, the filtrate was evaporated to remove the solvent, and ice ether was used for precipitation three times to obtain a brown precipitate. The collected precipitate was separated and purified by column chromatography (DCM: MeOH = 10: 1) to obtain docosahexaenoic acid-polyethylene glycol conjugate I-VI.
[0093] Example 3 Synthesis of Docosahexaenoic Acid-Polyethylene Glycol Conjugate 2 (DHA2-PEG)
[0094] Synthesis route such as Figure 4 As shown:
[0095] 1. Synthesis of succinimidyl-modified docosahexaenoic acid
[0096] In a 100ml round-bottom flask equipped with a spherical condenser, N-hydroxysuccinimide (NHS, 207mg, 1.8mmol) and docosahexaenoic acid (DHA, 500mg, 1.5mmol) were added in sequence and dissolved in 4ml of anhydrous dichloromethane, and then 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide (EDC, 279mg, 1.8mmol) and N,N-diisopropylethylamine (DIEA, 233mg, 1.8mmol) were quickly added dropwise. The reaction was observed by thin layer chromatography (developing solvent: DCM: MeOH = 100:1). When the reaction was basically completed, the reaction solution was cooled and then washed with 5% citric acid, saturated sodium bicarbonate, and saturated brine respectively. The organic layer was dried over anhydrous sodium sulfate and filtered after complete drying. The filtrate was evaporated to remove the solvent. The product succinimidyl-modified docosahexaenoic acid (yellow liquid, 588 mg, yield 92.1%) was separated and purified by column chromatography (DCM:MeOH=100:1).
[0097] 2. Synthesis of Lysine-Docosahexaenoic Acid Conjugate
[0098] Lysine (Lysine, 49 mg, 0.336 mmol) and succinimidyl-modified docosahexaenoic acid (DHA-NHS, 300 mg, 0.705 mmol) were added to a 100 ml round-bottom flask equipped with a spherical condenser, dissolved in 4 ml of anhydrous dichloromethane, and then N, N-diisopropylethylamine (DIEA, 91 mg, 0.705 mmol) was quickly added dropwise. Stir overnight at 43 ° C, and observe the reaction by thin layer chromatography (developing solvent: DCM: MeOH = 10: 1). When the reaction is basically over, cool the reaction solution, and then wash it with 5% citric acid, saturated sodium bicarbonate, and saturated brine respectively. The organic layer was dried over anhydrous sodium sulfate and filtered after complete drying. The filtrate was evaporated to remove the solvent. The product lysine-docosahexaenoic acid conjugate (yellow liquid, 211.2 mg, yield 81.9%) was separated and purified by column chromatography (DCM: MeOH = 10: 1).
[0099] Product 1 H NMR spectra and peak assignments are as follows Figure 5 As shown, the equivalent covalent linkage between lysine and docosahexaenoic acid was demonstrated, and the obtained product was confirmed to be the target product with high purity.
[0100] 3. Synthesis of Docosahexaenoic Acid-Polyethylene Glycol Conjugate 2 (DHA2-PEG) In a 100 ml round-bottom flask equipped with a spherical condenser, polyethylene glycol (mPEG 2k-NH2, 0.558g, 0.279mmol), lysine-docosahexaenoic acid conjugate (Lysine-DHA2, 0.257g, 0.335mmol) were dissolved in 4ml of anhydrous dichloromethane, and then 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide (EDC, 0.052g, 0.335mmol) and N,N-diisopropylethylamine (DIEA, 0.043g, 0.335mmol) were quickly added dropwise. Stir overnight at 43°C, and the reaction was observed by thin layer chromatography (developing solvent: DCM: MeOH = 10:1). When the reaction was basically completed, the reaction solution was cooled, the filtrate was evaporated to remove the solvent, and ice ether was used for precipitation three times to obtain a brown precipitate. The collected precipitate was separated and purified by column chromatography (DCM:MeOH=10:1) to obtain docosahexaenoic acid-polyethylene glycol conjugate 2 (slightly yellow solid, 0.580 g, yield 74.2%).
[0101] Product 2 1 H NMR spectra and peak assignments are as follows Figure 6 As shown, a 1:2 equivalent covalent linkage between polyethylene glycol and docosahexaenoic acid was demonstrated, and the obtained product was confirmed to be a highly pure target product.
[0102] Example 4 Synthesis of Docosahexaenoic Acid-Polyethylene Glycol Conjugate 3 (DHA2-PEG)
[0103] The synthesis process of conjugate VIII is shown in Figure 7.
[0104] 1. Synthesis of polyethylene glycol-isopropyl glycerol
[0105] In a 100 ml round bottom flask equipped with a spherical condenser, polyethylene glycol (mPEG 2k-COOH, 0.558g, 0.279mmol), isopropyl glycerol (0.044g, 0.335mmol) and 4-dimethylaminopyridine (DMAP, 0.041g, 0.335mmol) were dissolved in 4ml of anhydrous dichloromethane, and then 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide (EDC, 0.052g, 0.335mmol) was quickly added dropwise. Stir overnight at 43°C, and the reaction was observed by thin layer chromatography (developing solvent: DCM: MeOH = 20:1). When the reaction was basically completed, the reaction solution was cooled, the filtrate was evaporated to remove the solvent, and precipitated three times with ice ether to obtain a precipitate. The dried precipitate, 1mL of dichloromethane and 0.25mL of ice trifluoroacetic acid were added to a 100ml round-bottom flask equipped with a spherical condenser, reacted at -20°C for 30 minutes, and 2mol / L of sodium hydroxide solution was added to neutralize. Then, the product was washed with 5% citric acid, saturated sodium bicarbonate, and saturated saline, respectively. The organic layer was dried over anhydrous sodium sulfate and filtered after complete drying. The filtrate was evaporated to remove the solvent. The product was separated and purified by column chromatography (DCM: MeOH = 10:1).
[0106] 2. Synthesis of Docosahexaenoic Acid-Polyethylene Glycol Conjugate 3 (DHA2-PEG)
[0107] In a 100 ml round-bottom flask equipped with a spherical condenser, polyethylene glycol-isopropyl glycerol (0.500 g, 0.235 mmol), docosahexaenoic acid conjugate (DHA, 0.170 g, 0.516 mmol) and 4-dimethylaminopyridine (DMAP, 29 mg, 0.516 mmol) were added in sequence and dissolved in 4 ml of anhydrous dichloromethane, and then 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide (EDC, 0.080 g, 0.516 mmol) was quickly added dropwise. Stirred overnight at 43 ° C, and the reaction was observed by thin layer chromatography (developing solvent: DCM: MeOH = 10: 1). When the reaction was basically completed, the reaction solution was cooled, the filtrate was evaporated to remove the solvent, and precipitated with ice ether three times to obtain a brown-yellow precipitate. The collected precipitate was separated and purified by column chromatography (DCM: MeOH = 10: 1) to obtain docosahexaenoic acid-polyethylene glycol conjugate 3.
[0108] Example 5 Preparation of drug-loaded nanomicelles
[0109] 7.6 mg of docosahexaenoic acid-polyethylene glycol conjugate 2 (DHA2-PEG) was dissolved in 0.1 mL of DMSO to prepare a first solution of 76 mg / mL; 0.4 mg of cabazitaxel was dissolved in 0.1 mL of DMSO to prepare a second solution of 4 mg / mL; the first solution and the second solution were mixed evenly at a volume ratio of 1:1, and 0.2 mL of the DMSO solution mixed with the two drugs was slowly injected into 4 mL of ultrapure water under ultrasonic vibration to make the solutions evenly mixed and quickly assemble micelles to form drug-loaded nanomicelle drugs. The residual dimethyl sulfoxide was removed by dialysis. The particle size distribution and transmission electron microscopy of the nanoparticles are shown in Figure 2. Figure 8 , 9 As shown, the nanomicelles are monodisperse and uniformly distributed, the particle diameter is about 12 nm, and the morphology is a regular spherical shape.
[0110] Example 6 Preparation of DHA2-PEG modified prodrug self-assembly
[0111] 1. Synthesis route of prodrug DHA-FL118 Fig.10 As shown, the synthesis process is as follows:
[0112] In a 100 ml round-bottom flask equipped with a spherical condenser, FL118 (100 mg, 0.25 mmol) and docosahexaenoic acid (DHA, 92 mg, 0.28 mmol) were added in sequence and dissolved in 4 ml of anhydrous dichloromethane, and then 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide (EDC, 43 mg, 0.28 mmol) and N,N-diisopropylethylamine (DIEA, 36 mg, 0.28 mmol) were quickly added dropwise. The reaction was observed by thin layer chromatography (developing solvent: DCM: MeOH = 20:1). When the reaction was basically completed, the reaction solution was cooled and then washed with 5% citric acid, saturated sodium bicarbonate, and saturated brine respectively. The organic layer was dried over anhydrous sodium sulfate and filtered after complete drying. The filtrate was evaporated to remove the solvent. The product DHA-FL118 (yellow solid, 122 mg, yield 67.5%) was separated and purified by column chromatography (DCM: MeOH = 20:1).
[0113] Product 1 H NMR spectra and peak assignments are as follows Fig.11 As shown, the equivalent covalent linkage between FL118 and docosahexaenoic acid was demonstrated, and the obtained product was confirmed to be the target product with high purity.
[0114] 2. The preparation process of DHA2-PEG modified prodrug self-assembly is as follows:
[0115] Dissolve 10 mg of docosahexaenoic acid-polyethylene glycol conjugate 2 (DHA2-PEG) in 0.5 mL of DMSO to prepare a first solution of 20 mg / mL; dissolve 18.4 mg of DHA-FL118 (containing 10 mg of FL118) in 0.5 mL of DMSO to prepare a second solution of 20 mg / mL; mix the first solution and the second solution in a volume ratio of 1:1, and slowly inject 1 mL of the DMSO solution mixed with the two drugs into 10 mL of ultrapure water under ultrasonic vibration to mix the solutions evenly and quickly assemble micelles to form DHA2-PEG-modified prodrug self-assemblies (DF / DHA2-PEG). Remove residual dimethyl sulfoxide by dialysis. The particle size distribution and transmission electron microscopy of the nanoparticles are shown in Figure 2. Fig.12 , 13 As shown, the nanoparticles are monodispersed and uniformly distributed, the particle diameter is about 145 nm, and the morphology is a regular spherical shape.
[0116] Example 7 Preparation of FL118 prodrug liposomes
[0117] In order to prepare FL118 prodrug lipid nanoparticles with a drug loading of 5% and a final drug concentration of 1 mg / mL, a lipid mixture of lecithin, cholesterol and DHA2-PEG with a mass ratio of 14:2:3 was first dissolved in 60 μL of ethanol, and then fully mixed with DHA-FL118 prodrug molecules dissolved in 1 mL of acetone. The mixture was slowly dripped into water while stirring. After stirring for 10 minutes, the remaining acetone was removed by a rotary evaporator to obtain uniformly dispersed lipid particles. The mixture was extruded through a 400nm polycarbonate film with an extruder to prepare the FL118 prodrug liposomes. The nanoparticle size distribution and transmission electron microscopy are shown in Figure 2. Fig.14 , 15 As shown, the nanoparticles are monodispersed and uniformly distributed, the particle diameter is about 150 nm, and the morphology is a vesicle-type structure, indicating that the prepared liposomes are large unilamellar liposomes.
[0118] Example 8 In vitro stability test of DF and DF / DHA2-PEG
[0119] In order to verify that the modification of DHA2-PEG increases the stability of the prodrug self-assembly, DHA-FL118 prodrug self-assembly without DHA2-PEG modification (DF) and DHA-FL118 prodrug self-assembly with DHA2-PEG modification (DF / DHA2-PEG) were prepared respectively.
[0120] The nanoparticles were stored at 37°C and the particle size was measured by dynamic light scattering every day, with three parallel samples measured each time. Fig.16 shown.
[0121] The results showed that DF / DHA2-PEG could remain stable for at least 30 days, while DF showed obvious precipitation on the 7th day, and its stability was much lower than that of DF / DHA2-PEG, proving the stabilizing effect of DHA2-PEG on nanoparticles.
[0122] Example 9 Cellular endocytosis of nanomicelles labeled with different DiIs
[0123] Since the surface PEGylation of the particles can easily reduce the interaction between the tumor cell membrane and the nanoparticles, it hinders the drug-loaded nanoparticles from entering the tumor cells to play a killing role. DiI was used as a fluorescent molecule to label the DHA2-PEG micelles in Example 5; the commercially available material DSPE-PEG 2k Substituting DHA2-PEG in Example 5, DiI-labeled DSPE-PEG was prepared 2k Micelles (DSPE-PEG 2k To investigate the effects of DHA2-PEG micelles and DSPE-PEG 2k The in vitro endocytosis of micelles and particle entry experiments were further investigated.
[0124] HCT116 cells were seeded in six-well plates at a density of 2 × 10 5 / well, and incubate at 37°C overnight. 2k micelles (500nmol / LDiI) were added to the cells and incubated at 37℃ for different time periods. Cells incubated with normal culture medium were used as controls. The cells were digested and collected, washed three times with PBS, and analyzed for cellular endocytosis using flow cytometry.
[0125] like Fig.17 As shown in Figure 2, the in vitro endocytosis of DHA2-PEG micelles was significantly higher than that of DSPE-PEG 2k micelles, suggesting that it has faster and stronger cell-killing ability.
[0126] Example 10 Endocytosis of Self-assembled Nanoparticles Labeled with Different DiIs
[0127] Since the surface PEGylation of the particles can easily reduce the interaction between the tumor cell membrane and the nanoparticles, it hinders the drug-loaded nanoparticles from entering the tumor cells to play a killing role. DiI was used as a fluorescent molecule to label the DF / DHA2-PEG in Example 6; the commercially available material DSPE-PEG was selected 2k Substituting DHA2-PEG in Example 6, DiI-labeled DSPE-PEG was prepared2k Modified self-assembled nanoparticles (DF / DSPE-PEG 2k ). To investigate DF, DF / DSPE-PEG 2k The in vitro cellular endocytosis of DF / DHA2-PEG and the nanoparticle entry experiment were further investigated.
[0128] HCT116 cells were seeded in six-well plates at a density of 2 × 10 5 / well, and cultured at 37°C overnight. 2k DF / DHA2-PEG (500nmol / L DiI) was added to the cells and incubated at 37°C for different time periods. Cells incubated with normal culture medium were used as controls. The cells were digested and collected, washed three times with PBS, and the cellular endocytosis was analyzed by flow cytometry.
[0129] like Fig.18 As shown in Figure 2, the in vitro cellular endocytosis of DF / DHA2-PEG was significantly higher than that of DF / DSPE-PEG. 2k , suggesting that it has faster and stronger cell-killing ability.
[0130] Example 11 In vitro cytotoxicity experiments of different drugs
[0131] In order to compare with the commonly used PEG-phospholipid materials, the commercially available material DSPE-PEG 2k Substituting DHA2-PEG in Example 6, DSPE-PEG was prepared 2k Modified self-assembled nanoparticles (DF / DSPE-PEG 2k ). The killing effects of different nanoparticles on tumor cells HCT116 and LoVo were investigated by CCK8, and free FL118 was used as a reference. The results are shown in Table 1.
[0132] Table 1. Determination of cell viability after 72 hours of drug action IC 50 ±SD(nM)
[0133]
[0134]
[0135] The results in Table 1 show that the antitumor activity of the prodrug nanoparticles DF / DHA2-PEG prepared in Example 6 is higher than that of DF and DF / DSPE-PEG 2k .
[0136] Example 12 In vitro cytotoxicity experiment of DHA2-PEG
[0137] The killing effect of DHA2-PEG on normal cell lines Raw264.7, HUVEC and 293T was investigated by CCK8. Fig. 20 The results show that the DHA2-PEG prepared in Example 3 has extremely low cytotoxicity to normal cell lines.
[0138] Example 13 In vivo toxicity experiment of DHA2-PEG
[0139] ICR mice (about 25 g each) were used as experimental subjects to evaluate the in vivo toxicity of DHA2-PEG. A total of 2 groups were divided into 4 mice in each group. The experimental group was injected with 300 μL of DHA2-PEG solution through the tail vein, and the control group was injected with the same volume of PBS. The injection was once every 3 days, for a total of 3 injections. The changes in the weight and blood cell count of the mice were measured and recorded within 14 days after administration.
[0140] Changes in mouse body weight and blood cell count Fig.21 , 22 As shown, it is shown that the DHA2-PEG prepared in Example 3 has no obvious in vivo toxicity.
Claims
1. Use of a docosahexaenoic acid-polyethylene glycol conjugate as a drug delivery carrier material for promoting intracellular delivery in the preparation of a pharmaceutical preparation, characterized in that: The conjugate comprises a hydrophilic segment and a hydrophobic segment, wherein the hydrophilic segment is a methoxy polyethylene glycol molecule with a molecular weight of 500 to 10,000, and the hydrophobic segment is 1 to 4 docosahexaenoic acid molecules.
2. The use according to claim 1, characterized in that The structural formula of the conjugate is shown in any one of formulas (I) to (X), Among them, the structural formula of R1 is: The structural formula of R2 is: n is an integer from 10 to 230.
3. The use according to claim 2, characterized in that n is 23, 45, 114 or 227.
4. The use according to claim 1, characterized in that The preparation method of the docosahexaenoic acid-polyethylene glycol conjugate comprises: in the presence of a condensing agent and a catalyst, docosahexaenoic acid and methoxy polyethylene glycol having a structural formula as shown in formula (XI) and R being a hydroxyl group or an amino group are subjected to a condensation reaction to obtain a DHA-PEG conjugate; Alternatively, under the action of a condensing agent and a catalyst, docosahexaenoic acid is first subjected to a condensation reaction with a linker compound having two or more linking groups, wherein the linking group is selected from a hydroxyl group, an amino group, and a carboxyl group; and then subjected to a condensation reaction with a methoxy polyethylene glycol having a structural formula as shown in formula (XI), wherein R is a hydroxyl group, an amino group, or a carboxyl group, to obtain a DHA-PEG conjugate. Wherein n is an integer from 10 to 230.
5. The use according to claim 4, characterized in that The linker compound is one of ethylene glycol, propylene glycol, butylene glycol, ethylenediamine, propylenediamine, butylenediamine, lysine, and isopropyl glycerol.
6. The use according to claim 4 or 5, characterized in that The condensation agent is 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide, and the catalyst is 4-dimethylaminopyridine or N,N-diisopropylethylamine.
7. The use according to claim 1, characterized in that include: The docosahexaenoic acid-polyethylene glycol conjugate and the hydrophobic drug are dissolved in organic solvents respectively, and the two are mixed and injected into the aqueous phase to form drug-loaded nanomicelles; Alternatively, the docosahexaenoic acid-polyethylene glycol conjugate and the prodrug modified with fatty acid are dissolved in organic solvents respectively, and the two are mixed and injected into the aqueous phase to form a docosahexaenoic acid-polyethylene glycol conjugate modified prodrug self-assembly; Alternatively, lecithin, cholesterol and docosahexaenoic acid-polyethylene glycol conjugate are added to a solution containing drug molecules to self-assemble to form drug-loaded liposomes.
8. The use according to claim 7, characterized in that When preparing drug-loaded nanomicelles, the mass ratio of docosahexaenoic acid-polyethylene glycol conjugate to hydrophobic drug is 1 to 40:1; preparing a prodrug self-assembly modified with a docosahexaenoic acid-polyethylene glycol conjugate, wherein the mass ratio of the docosahexaenoic acid-polyethylene glycol conjugate to the prodrug is 1 to 20:1; When preparing the drug-encapsulated liposome, the mass ratio of lecithin, cholesterol, docosahexaenoic acid-polyethylene glycol conjugate and the drug is 10-40:1-8:3:1-10.
